Skip to main content

Table 5 Incremental cost-effectiveness ratio (expressed in euros per QALY) in the univariate analysis

From: Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vsobservation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study

Parameter value Gemcitabine (n = 154) Erlotinib (n = 155)
Base case 76,625 184,733
Gemcitabine tariff   
 –30% 47,132
Erlotinib tariff   
 –30% 125,957
Pemetrexed tariff   
 –30% 79,749 188,212
Palliative care cost   
 €1,627 per month 81,021 183,772
 €3,021 per month 72,213 185,680
Utility score under observation   
 –10% 117,197 307 149
 +10% 57,136 130,727
Utility score under IV chemotherapy   
 –10% €117,197
 +10% €57,136
Utility score under oral chemotherapy   
 –10% €366,092
 +10% €124,060
  1. Incremental cost-effectiveness ratios (ICER) are expressed in euros/quality adjusted-life years (QALY). The sign “-” was used when the ICER was not affected by the univariate analysis.
  2. Legend: IV: intravenous.